[go: up one dir, main page]

AU2001280590A1 - 5-substituted 2-aryl-4-pyrimidinones - Google Patents

5-substituted 2-aryl-4-pyrimidinones

Info

Publication number
AU2001280590A1
AU2001280590A1 AU2001280590A AU8059001A AU2001280590A1 AU 2001280590 A1 AU2001280590 A1 AU 2001280590A1 AU 2001280590 A AU2001280590 A AU 2001280590A AU 8059001 A AU8059001 A AU 8059001A AU 2001280590 A1 AU2001280590 A1 AU 2001280590A1
Authority
AU
Australia
Prior art keywords
pyrimidinones
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280590A
Inventor
Dario Doller
Kevin J. Hodgetts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of AU2001280590A1 publication Critical patent/AU2001280590A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001280590A 2000-07-18 2001-07-18 5-substituted 2-aryl-4-pyrimidinones Abandoned AU2001280590A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21970300P 2000-07-18 2000-07-18
US60219703 2000-07-18
US60/219,703 2000-07-18
PCT/US2001/022513 WO2002006242A2 (en) 2000-07-18 2001-07-18 5-substituted 2-aryl-4-pyrimidinones

Publications (1)

Publication Number Publication Date
AU2001280590A1 true AU2001280590A1 (en) 2002-01-30

Family

ID=22820417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280590A Abandoned AU2001280590A1 (en) 2000-07-18 2001-07-18 5-substituted 2-aryl-4-pyrimidinones

Country Status (6)

Country Link
US (2) US6943173B2 (en)
EP (1) EP1301490A2 (en)
JP (1) JP2004504302A (en)
AU (1) AU2001280590A1 (en)
CA (1) CA2416248A1 (en)
WO (1) WO2002006242A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1636000A (en) * 2000-03-16 2005-07-06 神经能质公司 5-substituted arylpyrimidines
JP2004504302A (en) * 2000-07-18 2004-02-12 ニューロジェン・コーポレーション 5-substituted 2-aryl-4-pyrimidinone
MXPA04007026A (en) 2002-02-22 2004-10-11 Pharmacia & Up John Company Substituted pyrimidinones and pyrimidinthiones.
AU2003216591A1 (en) * 2002-04-10 2003-10-20 Orichid Chemicals And Pharmaceuticals Limited Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
US7112585B2 (en) 2003-04-18 2006-09-26 Bristol-Myers Squibb Company Pyrimidine derivatives as corticotropin releasing factor inhibitors
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
CA2522803A1 (en) * 2003-04-23 2004-11-04 Pharmacia & Upjohn Company Llc Substituted pyrimidinones and pyrimidinthiones as crf antagonists
JP4060235B2 (en) * 2003-05-22 2008-03-12 株式会社日立製作所 Disk array device and disk array device control method
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
AU2005244104B2 (en) 2004-05-08 2012-03-15 Novartis International Pharmaceutical Ltd. 4,5-disubstituted-2-aryl pyrimidines
CA2692039C (en) * 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
WO2009100403A1 (en) * 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
WO2011109267A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
TW201720796A (en) 2015-10-14 2017-06-16 必治妥美雅史谷比公司 2,4-dihydroxynicotinamide as an APJ agonist
ES2858312T3 (en) 2015-12-04 2021-09-30 Bristol Myers Squibb Co Apelin receptor agonists and methods of use
WO2017106396A1 (en) 2015-12-16 2017-06-22 Bristol-Myers Squibb Company Heteroarylhydroxypyrimidinones as agonists of the apj receptor
BR112018068341A2 (en) 2016-03-24 2019-01-15 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1122533B (en) * 1959-04-18 1962-01-25 Knoll Ag Chemischer Fabriken Process for the preparation of basic substituted 4-amino-6-hydroxypyrimidines
DE3423622A1 (en) * 1984-06-27 1986-01-02 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING PHOSPHORIC ACID DERIVATIVES AND INTERMEDIATE PRODUCTS
DE3423623A1 (en) * 1984-06-27 1986-01-02 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING PHOSPHORIC ACID DERIVATIVES AND INTERMEDIATE PRODUCTS
GB9216272D0 (en) * 1991-08-15 1992-09-09 Ici Plc Substituted heterocycles
CA2133657A1 (en) 1992-04-16 1993-10-28 Peter R. Bernstein Substituted derivatives
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
WO1995026958A1 (en) * 1994-03-31 1995-10-12 Sanofi Winthrop, Inc. Pyrimidinyl derivatives as interleukin inhibitors
US6001814A (en) 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
DE69634122D1 (en) 1995-04-27 2005-02-03 Mitsubishi Pharma Corp Heterocyclic amide compounds and their use in medicine
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6288060B1 (en) * 1995-10-17 2001-09-11 Neurocrine Biosciences, Inc. Amino substituted pyrimidines and triazines
US6271238B1 (en) 1996-09-06 2001-08-07 Nippon Kayaku Kabushiki Kaisha Acetamide derivatives and protease inhibitors
EP0940400A4 (en) * 1996-10-25 2002-10-02 Mitsubishi Pharma Corp NOVEL HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USE FOR MEDICINAL PURPOSES
US6121202A (en) * 1997-11-07 2000-09-19 American Cyanamid Company Thienyloxypyridines and-pyrimidines useful as herbicidal agents
WO1999032459A1 (en) 1997-12-22 1999-07-01 Yoshitomi Pharmaceutical Industries, Ltd. Chymase inhibitors
ES2193589T3 (en) * 1998-01-20 2003-11-01 Warner Lambert Co ALDEHIDO OF THE ACID N- (2- (5-BENCILOXICARBONIL-AMINO-6-OXO-2- (4-FLUOROFENIL) -1,6-DIHIDRO-1-PYRIMIDINIL) ACETOXIL) -L-ASPARTICO AS AN INHIBITOR (IN VIVO) OF THE CONVERSION ENZYME OF INTERLEUCINA-1BETA.
TR200003513T2 (en) * 1998-06-02 2001-06-21 Osi Pharmaceuticals, Inc. Pirolo [2,3d] Pyrimidine compositions and uses
US6255453B1 (en) 1998-06-03 2001-07-03 Cortech, Inc. Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
US6680322B2 (en) * 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP2004504302A (en) * 2000-07-18 2004-02-12 ニューロジェン・コーポレーション 5-substituted 2-aryl-4-pyrimidinone

Also Published As

Publication number Publication date
WO2002006242A2 (en) 2002-01-24
JP2004504302A (en) 2004-02-12
EP1301490A2 (en) 2003-04-16
US20050234051A1 (en) 2005-10-20
US6943173B2 (en) 2005-09-13
CA2416248A1 (en) 2002-01-24
US20020052387A1 (en) 2002-05-02
WO2002006242A3 (en) 2002-07-18
US7169790B2 (en) 2007-01-30

Similar Documents

Publication Publication Date Title
AU2001262847A1 (en) Language-understanding
AU2001292739A1 (en) 1-oxorapamycins
AU2002211620A1 (en) Autoanastomosis
AU2001254546A1 (en) Aminopiperidines
AU2001220246A1 (en) Neckphone
AU2001296577A1 (en) Chlorophyllases
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2001280590A1 (en) 5-substituted 2-aryl-4-pyrimidinones
AU2002211128A1 (en) Step-bike
AU2001258924A1 (en) Microsatellite-aflp
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
IL146531A0 (en) 5-substituted arylpyrimidines
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2001291876A1 (en) Triazolo-epothilones
AU2001282644A1 (en) Case
AU2002214354A1 (en) Neck-phone
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001262711A1 (en) Cytoprotectors
AU2001295713A1 (en) Blast-processing
AU2001284173A1 (en) Calycins
AU2001260192A1 (en) Glycinamides
AU2001275014A1 (en) Imidazoloisoquinolines
AU5018801A (en) Offside-detection-system